Home > Boards > US Listed > Medical - Drugs > Abbvie (ABBV)

$abbv $100.83 ^ 0.91 (0.91%)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Taurus69 Member Profile
Member Level 
Followed By 196
Posts 26,909
Boards Moderated 166
Alias Born 08/30/12
160x600 placeholder
CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite PR Newswire (US) - 1/26/2021 8:45:00 AM
AbbVie: European Commission Approves Rinvoq to Treat Active Psoriatic Arthritis Dow Jones News - 1/25/2021 12:44:00 PM
European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondy... PR Newswire (US) - 1/25/2021 11:30:00 AM
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease GlobeNewswire Inc. - 1/25/2021 8:30:00 AM
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic ... PR Newswire (US) - 1/15/2021 9:00:00 AM
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma GlobeNewswire Inc. - 1/13/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/12/2021 4:32:13 PM
Allergan Aesthetics Enters Into Option to Acquire Cypris Medical PR Newswire (US) - 1/12/2021 4:05:00 PM
Dragonfly Therapeutics annonce l'option d'adhésion exercée par AbbVie concernant le médicament candidat d'immunothérapie ... PR Newswire (Canada) - 1/12/2021 12:35:00 PM
AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call PR Newswire (US) - 1/12/2021 8:00:00 AM
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate PR Newswire (US) - 1/12/2021 6:45:00 AM
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate PR Newswire (Canada) - 1/12/2021 6:45:00 AM
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate PR Newswire (US) - 1/12/2021 6:45:00 AM
AbbVie: Skyrizi Phase 3 Crohn's Induction Studies Meet Main Endpoints Dow Jones News - 1/7/2021 9:56:00 AM
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 I... PR Newswire (US) - 1/7/2021 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 5:01:07 PM
AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire (US) - 1/6/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:03:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:03:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:02:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:02:37 PM
AbbVie Reports Positive Phase 3 Results of Skyrizi in Psoriatic Arthritis Dow Jones News - 1/5/2021 10:14:00 AM
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Ps... PR Newswire (US) - 1/5/2021 8:48:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/31/2020 1:16:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/31/2020 1:15:03 PM
Taurus69 Member Level  Sunday, 07/19/20 04:25:45 PM
Re: None
Post # of 621 
$abbv $100.83 ^ 0.91 (0.91%)
Volume: 6,896,147 @07/17/20 7:51:43 PM EDT

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences